Physician profile
Peter Freswick
NPI 1699906263
$1,209.86
in general payments reported to CMS, 2019-2025
12 companies · $394 in 2025
The $394 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.26 · 2021: $50.58 · 2022: $203 · 2023: $200 · 2024: $340 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.11 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.35 | 2021-2024 | |
| Genzyme Corporation | $336.91 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.53 | 2022-2025 | Dupixent |
| Alcresta Therapeutics, INC. | $112.49 | 2025 | Relizorb |
| Takeda Pharmaceuticals U.S.A., INC. | $62.20 | 2022-2025 | |
| Janssen Biotech, INC. | $52.49 | 2025 | Tremfya |
| Medtronic, INC. | $39.81 | 2023 | Endoflip |
| Ars Pharmaceuticals Operations, INC. | $22.98 | 2025 | Neffy |
| Alexion Pharmaceuticals, INC. | $22.26 | 2019 | |
| Sandoz INC. | $22.18 | 2023 | Hyrimoz |
| Applied Medical Technology INC | $19.20 | 2024 | |
| Mirum Pharmaceuticals, INC. | $18.46 | 2024 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Freswick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.